Trial Profile
Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects with a Recent Acute Coronary Syndrome + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific-Site (version 1.0, dated 17-Dec-08).
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Acute coronary syndromes; Cardiovascular disorders
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms APPRAISE-2
- Sponsors Bristol-Myers Squibb
- 11 Jul 2022 Results assessing cardiovascular outcomes in patients with DM presenting with ACS, stratified by PAD status from 4 randomized post-ACS trials (PLATO, APPRAISE-2, TRILOGY, and TRACE) published in the American Journal of Cardiology.
- 15 Nov 2021 Results (N=47,474), pooled analysis of data from 4 multicenter randomized trials (APPRAISE-2, PLATO, TRACER and TRILOGY ACS) presented at the American Heart Association Scientific Sessions 2021
- 05 Oct 2021 This trial has been completed in France, according to European Clinical Trials Database record.